Soft Tissue Sarcoma (STS) - Market Insights, Epidemiology, and Market Forecast-2030

DelveInsight’s ‘Soft Tissue Sarcoma (STS) - Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of STS in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease, but the affected individuals may notice slow-growing, painless mass in the affected area.

According to DelveInsight’s, STS has various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to the majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
Soft Tissue Sarcoma (STS) - Disease Understanding and Treatment Algorithm

Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels, and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course.

Soft Tissue Sarcoma (STS) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM, Type-specific Incidence Cases of Soft Tissue Sarcoma (STS) in the 7MM, Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States, Total Incident Cases of STS including GIST in the United States and Incidence of STS by Extremities (%) in the 7MM scenario of STS in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017–2030.

According to DelveInsight’s, the total incident population of Soft Tissue Sarcoma (STS) in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).

Among all the seven major markets, the United States accounts for the highest number of cases of STS. In 2017, there were 12,390 incident cases of STS—which did not include GIST cases—in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total incident population of STS to 17,480 in 2017.

Soft Tissue Sarcoma (STS) Drug Chapters
STS is a heterogeneous group of malignancies and relatively rare that are characterized by mesodermal differentiation. It is primarily encountered in adults but can affect patients of any age. There are many histologic subtypes, and the malignancy can be low or high grade. Soft tissue sarcoma treatments may include surgery, chemotherapy, radiation therapy, or a combination of these therapies.

The emerging therapies are classified into four categories based on their line of therapy. The upcoming first-line therapies that are going to be launched in the forecasted period includes, AL3818 (anlotinib) and Fibromun. The second-line emerging therapies include Vigil in combination with irinotecan and temozolomide, AL3818, GSK 3377794, Ripretinib (DCC-2618), Tazemetostat, Abemaciclib, Pembrolizumab, Crizotinib, ABI-009, and SRA737. The third-line emerging therapies include Avapritinib, Cabozantinib, and Selinexor. The fourth-line emerging therapies include Avapritinib, TAS-116, Crenolanib, and Ripretinib.

Soft Tissue Sarcoma (STS) Market Outlook
According to DelveInsight, the total market size of Soft Tissue Sarcoma (STS) excluding GIST in seven major markets was USD 246.7 million in 2017. The market size of STS is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the highest market size of STS. In 2017, the market size of STS (excluding GIST) was found to be USD 142.18 million.

Among EU5, Germany had the highest market size in 2017 with revenue USD 22.06 million, followed by Italy with revenue USD 18.84 million. The market size of STS (excluding GIST) in Japan was found to be USD 17.60 million in 2017.

Soft Tissue Sarcoma (STS) Drugs Uptake
The current market size of STS is mainly attributed to Votrient, Yondelis, Halaven, and various anthracycline and non-anthracycline regimens. The market size of GIST in the United States was found to be USD 119.7 million in 2017 and expected to increase during the forecast period (2020–2030) due to potential therapies Vitrakvi, Rozlytrek, Avapritinib, Ripretinib and others.

Soft Tissue Sarcoma (STS) Report Insights
• Patient Population by total incident cases
• Type-specific incident cases of STS
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Soft Tissue Sarcoma (STS) Report Key Strengths
• 11 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Soft Tissue Sarcoma (STS) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• SWOT Analysis
• Access and Reimbursement

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Soft Tissue Sarcoma (STS) market
• Organize sales and marketing efforts by identifying the best opportunities for Soft Tissue Sarcoma (STS) market
• To understand the future market competition in the Soft Tissue Sarcoma (STS) market.


1. Key Insights
2. Executive Summary of Soft-Tissue Sarcoma (STS)
3. Soft-Tissue Sarcomas (STS) Market Overview at a Glance
3.1. Market Share (%) Distribution of Soft-Tissue Sarcomas (STS) in 2017
3.2. Market Share (%) Distribution of Soft-Tissue Sarcomas (STS) in 2030
4. Soft-Tissue Sarcomas (STS): Disease Background and Overview
4.1. Introduction
4.2. Types of Soft-Tissue Sarcomas (STS)
4.3. The Molecular Biology of Soft-Tissue Sarcomas (STS)
4.4. Stages of Soft-Tissue Sarcomas (STS)
4.5. Diagnosis of Soft-Tissue Sarcomas (STS)
4.5.1. Medical History and Physical Exam
4.5.2. Imaging Tests
4.5.3. Biopsy
4.5.4. Pathological diagnosis of soft tissue sarcomas
4.5.5. Proposed Diagnostic Guidelines
5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Epidemiology and Market Methodology
5.3. 7MM Incident Patient Population of Soft Tissue Sarcoma (STS)
6. Case Reports
6.1. Neo-adjuvant chemotherapy for radiation-associated soft-tissue sarcoma (RAS): A case report
6.2. Soft-Tissue Sarcoma Masquerading as a Hematoma
6.3. Neo-adjuvant chemotherapy for primary sarcoma of the breast: a case report
7. Country Wise-Epidemiology of Soft Tissue Sarcoma (STS)
7.1. United States Epidemiology
7.1.1. Assumptions and Rationale
7.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United States
7.1.3. Type-Specific Incidence of STS in the United States
7.1.4. Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
7.1.5. Total Incident Cases of STS including GIST in the United States
7.1.6. Incidence of STS by Extremities (%) in the United States
7.2. EU5 Epidemiology
7.2.1. Germany
7.2.1.1. Assumptions and Rationale
7.2.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Germany
7.2.1.3. Gender-Specific Incidence of STS in Germany
7.2.1.4. Type-Specific Incidence of STS in Germany
7.2.1.5. Age-Specific Incidence of STS in Germany
7.2.1.6. Stage-Specific Incidence of STS in Germany
7.2.1.7. Incidence of STS by Extremities (%) in Germany
7.2.2. France
7.2.2.1. Assumptions and Rationale
7.2.2.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in France
7.2.2.3. Gender-Specific Incidence of STS in France
7.2.2.4. Type-Specific Incidence of STS in France
7.2.2.5. Age-Specific Incidence of STS in France
7.2.2.6. Stage-Specific Diagnosed Incidence of STS in France
7.2.2.7. Incidence of STS by Extremities (%) in France
7.2.3. Italy
7.2.3.1. Assumptions and Rationale
7.2.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Italy
7.2.3.3. Gender-Specific Incidence of STS in Italy
7.2.3.4. Type-Specific Incidence of STS in Italy
7.2.3.5. Age-Specific Incidence of STS in Italy
7.2.3.6. Stage-Specific Diagnosed Incidence of STS in Italy
7.2.3.7. Incident of STS by Extremities (%) in Italy
7.2.4. Spain
7.2.4.1. Assumptions and Rationale
7.2.4.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Spain
7.2.4.3. Gender-Specific Incidence of STS in Spain
7.2.4.4. Type-Specific Incidence of STS in Spain
7.2.4.5. Age-Specific Incidence of STS in Spain
7.2.4.6. Stage-Specific Incidence of STS in Spain
7.2.4.7. Incident of STS by Extremities (%) in Spain
7.2.5. United Kingdom
7.2.5.1. Assumptions and Rationale
7.2.5.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United Kingdom
7.2.5.3. Gender-Specific Incidence of STS in the United Kingdom
7.2.5.4. Type-Specific Incidence of STS in the United Kingdom
7.2.5.5. Age-Specific Incidence of STS in the United Kingdom
7.2.5.6. Stage-Specific Diagnosed Incidence of STS in the United Kingdom
7.2.5.7. Incident of STS by Extremities (%) in the United Kingdom
7.3. Japan Epidemiology
7.3.1. Assumptions and Rationale
7.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Japan
7.3.3. Gender-Specific Incidence of STS in Japan
7.3.4. Type-Specific Incidence of STS in Japan
7.3.5. Age-Specific Incidence of STS in Japan
7.3.6. Stage-Specific Incidence of STS in Japan
7.3.7. Incident of STS by Extremities (%) in Japan
8. Treatment and Management of Soft Tissue Sarcoma (STS)
8.1. Stage-wise Treatment
8.2. Treatment Algorithms
8.3. Treatment Guidelines
8.3.1. UK guidelines for the management of soft tissue sarcomas
8.3.2. NCCN guidelines for the management of soft tissue sarcomas
8.3.3. Soft Tissue and Visceral Sarcomas: ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
9. Unmet Needs
10. Marketed Drugs
10.1. Halaven (Eribulin Mesylate): Eisai
10.1.1. Product Description
10.1.2. Regulatory Milestones
10.1.3. Clinical Development
10.1.4. Ongoing Current Pipeline Activity
10.1.5. Safety and efficacy
10.1.6. Product Profile
10.2. Gleevec (Imatinib Mesylate): Novartis
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Clinical Development
10.2.4. Safety and efficacy
10.2.5. Product Profile
10.3. Yondelis (Trabectedin): Pharma Mar
10.3.1. Product Description
10.3.2. Regulatory Milestones
10.3.3. Clinical Development
10.3.4. Safety and efficacy
10.3.5. Product Profile
10.4. Lartruvo (Olaratumab): Eli Lilly
10.4.1. Product Description
10.4.2. Regulatory Milestones
10.4.3. Clinical Development
10.4.4. Safety and efficacy
10.4.5. Product Profile
10.5. Vitrakvi (Larotrectinib; BAY2757556): Bayer/Loxo Oncology
10.5.1. Product Description
10.5.2. Regulatory Milestones
10.5.3. Clinical Development
10.5.4. Safety and efficacy
10.5.5. Product Profile
10.6. Stivarga (Regorafenib): Bayer
10.6.1. Product Description
10.6.2. Regulatory Milestones
10.6.3. Clinical Development
10.6.4. Ongoing Current Pipeline Activity
10.6.5. Safety and efficacy
10.6.6. Product Profile
10.7. Sutent (Sunitinib malate): Pfizer
10.7.1. Product Description
10.7.2. Regulatory Milestones
10.7.3. Clinical Development
10.7.4. Safety and efficacy
10.7.5. Product Profile
10.8. Votrient (Pazopanib): GlaxoSmithKline/Novartis
10.8.1. Product Description
10.8.2. Regulatory Milestones
10.8.3. Clinical Development
10.8.4. Ongoing Current Pipeline Activity
10.8.5. Safety and efficacy
10.8.6. Product Profile
10.9. Vincristine Sulfate: Hospira
10.9.1. Product Description
10.9.2. Regulatory Milestones
10.9.3. Product Profile
10.10. Rozlytrek (Entrectinib): Roche (Genentech)
10.10.1. Product Description
10.10.2. Regulatory Milestones
10.10.3. Safety and Efficacy of Rozlytrek
10.10.4. Clinical trial information
10.10.5. Product Profile
11. Emerging Drugs
11.1. Key Cross Competition
Phase III Emerging Molecules
11.2. Avapritinib (BLU-285): Blueprint Medicines Corporation
11.2.1. Product Description
11.2.2. Other Development Activities
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.3. Vigil (In combination with irinotecan and temozolomide): Gradalis
11.3.1. Product Description
11.3.2. Other Development Activities
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.4. Anlotinib (AL3818): Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical
11.4.1. Product Description
11.4.2. Other Development Activities
11.4.3. Clinical Development
11.4.4. Clinical Trials Information
11.4.5. Safety and Efficacy
11.4.6. Product Profile
11.5. Selinexor: Karyopharm Therapeutics
11.5.1. Product Description
11.5.2. Other Development Activities
11.5.3. Clinical Development
11.5.4. Clinical Trials Information
11.5.5. Safety and Efficacy
11.5.6. Product Profile
11.6. Aldoxorubicin (INNO-206): CytRx
11.6.1. Product Description
11.6.2. Other Development Activities
11.6.3. Clinical Development
11.6.4. Clinical Trials Information
11.6.5. Safety and Efficacy
11.6.6. Product Profile
11.7. Ripretinib (DCC-2618): Deciphera Pharmaceuticals
11.7.1. Product Description
11.7.2. Other Development Activities
11.7.3. Clinical Development
11.7.4. Clinical Trials Information
11.7.5. Safety and Efficacy
11.7.6. Product Profile
11.8. Fibromun (In combination with Doxorubicin): Philogen
11.8.1. Product Description
11.8.2. Other Development Activities
11.8.3. Clinical Development
11.8.4. Clinical Trials Information
11.8.5. Product Profile
11.9. Hensify (NBTXR3): Nanobiotix
11.9.1. Product Description
11.9.2. Other Development Activities
11.9.3. Clinical Development
11.9.4. Clinical Trials Information
11.9.5. Safety and efficacy
11.9.6. Product Profile
11.10. Crenolanib: Arog Pharmaceuticals
11.10.1. Product Description
11.10.2. Other Development Activities
11.10.3. Clinical Development
11.10.4. Clinical Trials Information
11.10.5. Safety and Efficacy
11.10.6. Product Profile
11.11. TAS-116: Taiho Pharmaceutical
11.11.1. Product Description
11.11.2. Clinical Development
11.11.3. Clinical Trials Information
11.11.4. Safety and Efficacy
11.11.5. Product Profile
Phase II Emerging Molecules
11.12. GSK3377794: GlaxoSmithKline/ Adaptimmune
11.12.1. Product Description
11.12.2. Other Development Activities
11.12.3. Clinical Development
11.12.4. Clinical Trials Information
11.12.5. Safety and Efficacy
11.12.6. Product Profile
11.13. ADP-A2M4: Adaptimmune
11.13.1. Product Description
11.13.2. Other Development Activities
11.13.3. Clinical Development
11.13.4. Clinical Trials Information
11.13.5. Safety and Efficacy
11.13.6. Product Profile
11.14. Tazemetostat (EPZ-6438): Epizyme
11.14.1. Product Description
11.14.2. Other Developmental Activities
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
11.14.5. Safety and Efficacy
11.14.6. Product Profile
11.15. AMG 337: NantPharma/ Amgen
11.15.1. Product Description
11.15.2. Other Development Activities
11.15.3. Clinical Development
11.15.4. Clinical Trials Information
11.15.5. Safety and Efficacy
11.15.6. Product Profile
11.16. GB226/APL-501: Genor Biopharma /Apollomics (Previously CBT Pharmaceuticals)
11.16.1. Product Description
11.16.2. Other Development Activities
11.16.3. Clinical Development
11.16.4. Clinical Trials Information
11.16.5. Product Profile
11.17. Camsirubicin: Monopar Therapeutics /Gem Pharmaceuticals
11.17.1. Product Description
11.17.2. Other Development Activities
11.17.3. Clinical Development
11.17.4. Clinical Trials Information
11.17.5. Safety and Efficacy
11.17.6. Product Profile
11.18. LTX-315: Lytix Biopharma
11.18.1. Product Description
11.18.2. Other Development Activities
11.18.3. Clinical Development
11.18.4. Clinical Trials Information
11.18.5. Safety and Efficacy
11.18.6. Product Profile
11.19. Abemaciclib (LY2835219): Eli Lilly and Company
11.19.1. Product Description
11.19.2. Other Development Activities
11.19.3. Clinical Development
11.19.4. Clinical Trials Information
11.19.5. Safety and Efficacy
11.19.6. Product Profile
11.20. Pembrolizumab: Merck Sharp & Dohme Corp.
11.20.1. Product Description
11.20.2. Other Development Activities
11.20.3. Clinical Development
11.20.4. Clinical Trials Information
11.20.5. Safety and Efficacy
11.20.6. Product Profile
11.21. Crizotinib (PF-02341066): Pfizer
11.21.1. Product Description
11.21.2. Other Development Activities
11.21.3. Clinical Development
11.21.4. Clinical Trials Information
11.21.5. Safety and Efficacy
11.21.6. Product Profile
11.22. ABI-009: Aadi Bioscience
11.22.1. Product Description
11.22.2. Other Development Activities
11.22.3. Clinical Development
11.22.4. Clinical Trials Information
11.22.5. Safety and Efficacy
11.22.6. Product Profile
11.23. Nivolumab: Bristol-Myers Squibb
11.23.1. Product Description
11.23.2. Other Development Activities
11.23.3. Clinical Development
11.23.4. Clinical Trials Information
11.23.5. Safety and Efficacy
11.23.6. Product Profile
11.24. Sorafenib Tosylate: Bayer
11.24.1. Product Description
11.24.2. Clinical Development
11.24.3. Clinical Trials Information
11.24.4. Safety and Efficacy
11.24.5. Product Profile
11.25. Doxorubicin with AGEN1884 and AGEN2034: Agenus
11.25.1. Product Description
11.25.2. Clinical Development
11.25.3. Clinical Trials Information
11.25.4. Product Profile
11.26. Apatinib Mesylate (In Combination with Doxorubicin and Ifosfamide: Jiangsu HengRui Medicine
11.26.1. Product Description
11.26.2. Clinical Development
11.26.3. Clinical Trials Information
11.26.4. Product Profile
11.27. Atezolizumab: Roche Pharma AG
11.27.1. Product Description
11.27.2. Clinical Development
11.27.3. Clinical Trials Information
11.27.4. Product Profile
11.28. Spartalizumab (PDR001): Novartis Pharmaceuticals
11.28.1. Product Description
11.28.2. Other Development Activities
11.28.3. Clinical Development
11.28.4. Clinical Trials Information
11.28.5. Product Profile
11.29. Iclusig (Ponatinib): Takeda
11.29.1. Product Description
11.29.2. Other Development Activities
11.29.3. Clinical Development
11.29.4. Clinical Trials Information
11.29.5. Safety and Efficacy
11.29.6. Product Profile
11.30. Temozolomide (Temodar): Merck
11.30.1. Product Description
11.30.2. Other Developmental Activities:
11.30.3. Clinical Development
11.30.4. Clinical trial information
11.30.5. Product Profile
11.31. Cabozantinib: Exelixis
11.31.1. Product Description
11.31.2. Other Developmental Activities:
11.31.3. Clinical Development
11.31.4. Clinical trial information
11.31.5. Safety and Efficacy
11.31.6. Product Profile
11.32. Avelumab: Merck KGaA
11.32.1. Product Description
11.32.2. Other Developmental Activities:
11.32.3. Clinical Development
11.32.4. Clinical trial information
11.32.5. Product Profile
Phase I/II Emerging Molecules
11.33. Lenvatinib (In Combination with Everolimus): Eisai
11.33.1. Product Description
11.33.2. Other Development Activities
11.33.3. Clinical Development
11.33.4. Clinical Trials Information
11.33.5. Product Profile
11.34. SRA737: Sierra Oncology
11.34.1. Product Description
11.34.2. Other Development Activities
11.34.3. Clinical Development
11.34.4. Clinical Trials Information
11.34.5. Safety and Efficacy
11.34.6. Product Profile
11.35. Nab-paclitaxel: Celgene
11.35.1. Product Description
11.35.2. Other Developmental Activities
11.35.3. Clinical Development
11.35.4. Clinical Trials Information
11.35.5. Safety and Efficacy
11.35.6. Product Profile
11.36. Afatinib: Boehringer Ingelheim
11.36.1. Product Description
11.36.2. Other Development Activities
11.36.3. Clinical Development
11.36.4. Clinical Trials Information
11.36.5. Safety and Efficacy
11.36.6. Product Profile
11.37. IMCnyeso (GSK01): GlaxoSmithKline/Immunocore
11.37.1. Product Description
11.37.2. Other Development Activities
11.37.3. Clinical Development
11.37.4. Clinical Trials Information
11.37.5. Product Profile
11.38. CAR-T/TCR-T Cell Immunotherapy: Shenzhen BinDeBio
11.38.1. Product Description
11.38.2. Other Development Activities
11.38.3. Clinical Development
11.38.4. Clinical Trials Information
11.38.5. Product Profile
11.39. Epirubicin Micelle (NC-6300; K-912): NanoCarrier
11.39.1. Product Description
11.39.2. Other Development Activities
11.39.3. Clinical Development
11.39.4. Clinical Trials Information
11.39.5. Safety and Efficacy
11.39.6. Product Profile
11.40. Copanlisib (BAY806946): Bayer
11.40.1. Product Description
11.40.2. Other Developmental Activities
11.40.3. Clinical Development
11.40.4. Clinical Trials Information
11.40.5. Product Profile
11.41. PLX9486: Plexxikon
11.41.1. Product Description
11.41.2. Clinical Development
11.41.3. Clinical Trials Information
11.41.4. Safety and Efficacy
11.41.5. Product Profile
11.42. BA3021: BioAtla
11.42.1. Product Description
11.42.2. Other Developmental Activities
11.42.3. Clinical Development
11.42.4. Clinical Trials Information
11.42.5. Product Profile
11.43. Tinostamustine (EDO-S101): Mundipharma-EDO GmbH
11.43.1. Product Description
11.43.2. Other Developmental Activities
11.43.3. Clinical Development
11.43.4. Clinical Trials Information
11.43.5. Safety and Efficacy
11.43.6. Product Profile
11.44. TBI-1301 (NY-ESO-1 T cell Receptor Gene Transduced Autologous T Lymphocytes): Takara Bio.
11.44.1. Product Description
11.44.2. Other Developmental Activities
11.44.3. Clinical Development
11.44.4. Clinical Trials Information
11.44.5. Safety and Efficacy
11.44.6. Product Profile
11.45. Ramucirumab (LY3009806): Eli Lilly and Company
11.45.1. Product Description
11.45.2. Clinical Development
11.45.3. Clinical Trials Information
11.45.4. Product Profile
11.46. TB-403: Oncurious NV
11.46.1. Product Description
11.46.2. Other Developmental Activities
11.46.3. Clinical Development
11.46.4. Clinical Trials Information
11.46.5. Product Profile
11.47. TLC178: Taiwan Liposome Company
11.47.1. Product Description
11.47.2. Other Development Activities
11.47.3. Clinical Development
11.47.4. Clinical Trials Information
11.47.5. Safety and Efficacy
11.47.6. Product Profile
11.48. Talimogene Laherparepvec (T-VEC): Amgen
11.48.1. Product Description
11.48.2. Other Developmental Activities
11.48.3. Clinical Development
11.48.4. Clinical Trials Information
11.48.5. Safety and Efficacy
11.48.6. Product Profile
11.49. MEK162: Array BioPharma
11.49.1. Product Description
11.49.2. Clinical Development
11.49.3. Clinical Trials Information
11.49.4. Safety and Efficacy
11.49.5. Product Profile
11.50. Neoadjuvant Durvalumab and Tremelimumab: AstraZeneca
11.50.1. Product Description
11.50.2. Clinical Development
11.50.3. Clinical Trials Information
11.50.4. Safety and Efficacy
11.50.5. Product Profile
11.51. Selpercatinib (LOXO-292): Eli Lilly/Loxo Oncology
11.51.1. Product Description
11.51.2. Other Development Activities
11.51.3. Clinical Development
11.51.4. Clinical Trials Information
11.51.5. Product Profile
12. Soft Tissue Sarcoma (STS): 7 Major Market Analysis
12.1. Key Findings
12.2. Market Size of metastatic Soft Tissue Sarcoma (STS) in the 7MM
12.3. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the 7MM
13. Market Outlook: The United States
13.1. United States Market Size
13.1.1. Total market size of Soft Tissue Sarcoma (STS)*
13.1.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the United States
14. Market Outlook: Europe
14.1. Germany
14.1.1. The total market size of Soft Tissue Sarcoma (STS)
14.1.2. Market Size of Soft Tissue Sarcoma (STS) by Therapies in Germany
14.2. France
14.2.1. Total Market size of Soft Tissue Sarcoma (STS)
14.2.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in France
14.3. Italy
14.3.1. Total Market size of Soft Tissue Sarcoma (STS)
14.3.2. Market Size of Soft Tissue Sarcoma (STS) by Therapies in Italy
14.4. Spain
14.4.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
14.4.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in Spain
14.5. United Kingdom
14.5.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
14.5.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the United Kingdom (UK)
15. Market Outlook: Japan
15.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
15.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in Japan
15.2.1. Market Size of metastatic Soft Tissue Sarcoma (STS) by First-line of Therapies in Japan
15.2.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Second-Line & Later Line Therapies in Japan
16. Access and Reimbursement Overview of Soft-Tissue Sarcoma (STS)
17. Market Drivers
18. Market Barriers
19. SWOT Analysis
20. Appendix
20.1. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Table 1 Summary of STS Market, Epidemiology, and Key Events (2017–2030)
Table 2 The IGF System in Sarcoma Pathogenesis
Table 3 Trunk and Extremities Sarcoma Stages
Table 4 Incident Patient Population of STS in the 7MM (2017–2030)
Table 5 Total Incident Population of STS in the United States (2017–2030)
Table 6 Type-Specific Incidence of STS in the US (2017–2030)
Table 7 Stage-Specific Incidence of STS (Excluding GIST) in the United States (2017–2030)
Table 8 Total Incident Population of GIST in the United States (2017–2030)
Table 9 Stage-Specific Incidence of GIST in the United States (2017–2030)
Table 10 Total Incident Population of STS including GIST in the United States (2017–2030)
Table 11 Gender-Specific Incidence of STS in the United States (2017–2030)
Table 12 Age-Specific Incidence of STS in the United States (2017–2030)
Table 13 Incidence of STS* by Extremities (%) in the United States (2017–2030)
Table 14 Total Incident Population of STS in Germany (2017–2030)
Table 15 Gender-Specific Incidence of STS in Germany (2017–2030)
Table 16 Type-Specific Incidence of STS in Germany (2017–2030)
Table 17 Age-Specific Incidence of STS in Germany (2017–2030)
Table 18 Stage-Specific Incidence of STS in Germany (2017–2030)
Table 19 Incidence of STS by Extremities (%) in Germany (2017–2030)
Table 20 Total Incident Population of STS in France (2017–2030)
Table 21 Gender-Specific Incidence of STS in France (2017–2030)
Table 22 Type-Specific Incidence of STS in France (2017–2030)
Table 23 Age-Specific Incidence of STS in France (2017–2030)
Table 24 Stage-Specific Incidence of STS in France (2017–2030)
Table 25 Incidence of STS by Extremities (%) in France (2017–2030)
Table 26 Total Incident Population of STS in Italy (2017–2030)
Table 27 Gender-Specific Incidence of STS in Italy (2017–2030)
Table 28 Type-Specific Incidence of STS in Italy (2017–2030)
Table 29 Age-Specific Incidence of STS in Italy (2017–2030)
Table 30 Stage-Specific Incidence of STS in Italy (2017–2030)
Table 31 Incident of STS by Extremities (%) in Italy (2017–2030)
Table 32 Total Incident Population of STS in Spain (2017–2030)
Table 33 Gender-Specific Incidence of STS in Spain (2017–2030)
Table 34 Type-Specific Incidence of STS in Spain (2017–2030)
Table 35 Age-Specific Incidence of STS in Spain (2017–2030)
Table 36 Stage-Specific Incidence of STS in Spain (2017–2030)
Table 37 Incident of STS by Extremities (%) in Spain (2017–2030)
Table 38 Total Incident Population of STS in the United Kingdom (2017–2030)
Table 39 Gender-Specific Incidence of STS in the United Kingdom (2017–2030)
Table 40 Type-Specific Incidence of STS in the UK (2017–2030)
Table 41 Age-Specific Incidence of STS in the United Kingdom (2017–2030)
Table 42 Stage-Specific Incidence of STS in the United Kingdom (2017–2030)
Table 43 Incident of STS by Extremities (%) in the United Kingdom (2017–2030)
Table 44 Total Incident Population of STS in Japan (2017–2030)
Table 45 Gender-Specific Incidence of STS in Japan (2017–2030)
Table 46 Type-Specific Incidence of STS in Japan (2017–2030)
Table 47 Age-Specific Incidence of STS in Japan (2017–2030)
Table 48 Stage-Specific Incidence of STS in Japan (2017–2030)
Table 49 Incident of STS by Extremities (%) in Japan (2017–2030)
Table 50 Novel and Targeted Agents for the Treatment of Soft-Tissue Sarcomas
Table 51 Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America- United States Public Health Service Grading System)
Table 52 Recommended dressings for neonates with EB
Table 53 Marketed Drug analysis
Table 54 Halaven, Clinical Trial Description, 2020
Table 55 Halaven; Clinical Trial Description, 2020
Table 56 Gleevec (Imatinib Mesylate), Clinical Trial Description, 2020
Table 57 Yondelis (Trabectedin), Clinical Trial Description, 2020
Table 58 Lartruvo (Olaratumab); Clinical Trial Description, 2020
Table 59 Vitrakvi, Clinical Trial Description, 2020
Table 60 Stivarga, Clinical Trial Description, 2020
Table 61 Stivarga; Clinical Trial Description, 2020
Table 62 Sutent; Clinical Trial Description, 2020
Table 63 Pazopanib, Clinical Trial Description, 2020
Table 64 Pazopanib; Clinical Trial Description, 2020
Table 65 Emerging Key cross Competition
Table 66 Emerging Key cross Competition (continued)
Table 67 Avapritinib (BLU-285), Clinical Trial Description, 2020
Table 68 Vigil, Clinical Trial Description, 2020
Table 69 Anlotinib (AL3818), Clinical Trial Description, 2020
Table 70 Selinexor, Clinical Trial Description, 2020
Table 71 Aldoxorubicin, Clinical Trial Description, 2020
Table 72 DCC-2618, Clinical Trial Description, 2020
Table 73 Fibromun (L19TNF); Clinical Trial Description, 2020
Table 74 NBTXR3, Clinical Trial Description, 2020
Table 75 Crenolanib, Clinical Trial Description, 2020
Table 76 TAS-116, Clinical Trial Description, 2020
Table 77 GSK3377794, Clinical Trial Description, 2020
Table 78 ADP-A2M4, Clinical Trial Description, 2020
Table 79 Tazemetostat; Clinical Trial Description, 2020
Table 80 AMG 337; Clinical Trial Description, 2020
Figure 1 Common Types of Soft-Tissue Sarcomas (STS)
Figure 2 Angiosarcoma
Figure 3 Dermatofibrosarcoma protuberans (DFSP)
Figure 4 Several Growth Factor Signals Activate Cell Membrane Receptor Tyrosine Kinases Leading to Activation of Downstream Interacting Signal Transduction Pathways (PI3K/AKT, RAF/MAPK, and mTOR)
Figure 5 Grade Numbers of Soft-Tissue Sarcoma (STS)
Figure 6 Diagnosis of Soft-Tissue Sarcoma
Figure 7 Imaging Tests for Soft-Tissue Sarcoma (STS)
Figure 8 Incidence of STS in the 7MM (2017–2030)
Figure 9 Total Incident Cases of STS in the United States (2017–2030)
Figure 10 Type-Specific Incidence of STS in the United States (2017–2030)
Figure 11 Stage-Specific Incidence of STS (Excluding GIST) in the United States (2017–2030)
Figure 12 Total Incident Cases of GIST in the United States (2017–2030)
Figure 13 Stage-Specific Incidence of GIST in the United States (2017–2030)
Figure 14 Total Incident Cases of STS including GIST in the United States (2017–2030)
Figure 15 Gender-Specific Incidence of STS in the United States (2017–2030)
Figure 16 Age-Specific Incidence of STS in the United States (2017–2030)
Figure 17 Incidence of STS* by Extremities (%) in the United States (2017–2030)
Figure 18 Total Incident Cases of STS in Germany (2017–2030)
Figure 19 Gender-Specific Incidence of STS in Germany (2017–2030)
Figure 20 Type-Specific Incident of STS in Germany (2017–2030)
Figure 21 Age-Specific Incidence of STS in Germany (2017–2030)
Figure 22 Stage-Specific Incidence of STS in Germany (2017–2030)
Figure 23 Incidence of STS by Extremities (%) in Germany (2017–2030)
Figure 24 Total Incident Cases of STS in France (2017–2030)
Figure 25 Gender-Specific Incidence of STS in France (2017–2030)
Figure 26 Type-Specific Incident of STS in France (2017–2030)
Figure 27 Age-Specific Incidence of STS in France (2017–2030)
Figure 28 Stage-Specific of STS in France (2017–2030)
Figure 29 Incidence of STS by Extremities (%) in France (2017–2030)
Figure 30 Total Incident Cases of STS in Italy (2017–2030)
Figure 31 Gender-Specific Incidence of STS in Italy (2017–2030)
Figure 32 Type-Specific Incident of STS in Italy (2017–2030)
Figure 33 Age-Specific Incidence of STS in Italy (2017–2030)
Figure 34 Stage-Specific Incidence of STS in Italy (2017–2030)
Figure 35 Incident of STS by Extremities (%) in Italy (2017–2030)
Figure 36 Total Incident Cases of STS in Spain (2017–2030)
Figure 37 Gender-Specific Incidence of STS in Spain (2017–2030)
Figure 38 Type-Specific Incident of STS in Spain (2017–2030)
Figure 39 Age-Specific Incidence of STS in Spain (2017–2030)
Figure 40 Stage-Specific Incidence of STS in Spain (2017–2030)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook